AAV8-hCocH for Cocaine Use Disorder

Cocaine Dependence, in Remission Clinical Trial

Official title:

Intravenous Administration of AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04884594
• Other study ID #: 20-012225
• Secondary ID: 5UH3DA042492
• Status: Recruiting
• Phase: Phase 1
• Start date: October 8, 2021
• Est. completion date: December 2026

Study information

• Verified date: June 2024
• Source: Mayo Clinic
• Contact: Beth Martin, RRT
• Phone: 507-422-0647
• Email: Hooten.william[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.

Description:

This is a phase-I dose escalation clinical trial testing the safety and MTD of IV administration of AAV8-hCocH to subjects with a history of cocaine use disorder-sustained remission. Subjects who provide written informed consent, meet entry criteria, and do not have transduction inhibition to AAV8 (pre-existing AAV8 antibodies) will be eligible. Subjects will be enrolled sequentially every 2-3 months or longer between cohorts. Dose escalation may be initiated after a single subject has been safely dosed; maximum enzyme expression is anticipated at week 3-4. This escalation paradigm is intended to minimize the number of subjects exposed to sub-therapeutic doses. The starting dose is based on the expression and safety of AAV8-CocH in mice, rats and NHP, and previous human experience using AAV8-FVIII IV in hemophilia patients. The starting dose has a large safety margin (15-fold) from the NOAEL in NHP. Approximately 7 weeks after an injection, a decision to escalate to the next dose level will be made based on a review of safety parameters and CocH levels by the investigative team.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Non-treatment seeking male or females ages 18 to 65 years, inclusive.

• DSM-5 diagnosis of cocaine use disorder in sustained remission as confirmed by the PI's review of the medical record.

• Are motivated to abstain from cocaine use during the period of the study, as evidenced both by the judgment of the Investigator or designee and by compliance with the requirement to make regular clinic visits.

• In the opinion of the PI, be in good general health as determined by medical and psychiatric history, general clinical examination, vital signs, and laboratory tests.

• Have provided written informed consent. Subjects should be cooperative, willing and able to participate and adhere to the protocol requirements.

• Have hematology, chemistry, kidney and liver function laboratory tests that are within (+/- 10%) of the current Mayo Clinic standardized normal values.

• Show a baseline EKG that demonstrates normal sinus rhythm and conduction without clinically significant abnormalities or arrhythmias.

• Are willing to return to research area for follow-up.

Exclusion Criteria:

• They show detectable pre-existing immunity to the AAV8 capsid as measured by AAV8 transduction inhibition and AAV8 total antibodies.

• Evidence of HIV or hepatitis of any etiology.

• Creatinine = 1.5 mg/dL.

• Any disease or mental health condition at the physician's discretion that would prevent the subject from fully complying with the requirements of the study. The physician may exclude subjects with active alcohol abuse, other substance abuse or positive urine toxicology screen for substances of abuse.

• Pregnant &/or lactating. All lactating women will be excluded from study participation. Women of child-bearing potential must have a negative pregnancy test performed at screening visit, agree to use birth control throughout the study period, refrain from getting pregnant within the study period and consent to pregnancy testing throughout the study period. Men must agree to use barrier methods of birth control and refrain from fathering children within the next year.

• Morbid obesity (BMI > 40).

Related Conditions & MeSH terms

• Cocaine Dependence, in Remission
• Cocaine-Related Disorders

Intervention

Drug:
• AAV8-hCocH
2e12 vg/kg single infusion intravenous
• AAV8-hCocH
6e12 vg/kg single infusion intravenous
• AAV8-hCocH
4e12 vg/kg single infusion intravenous

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
W. Michael Hooten	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Number of participants with treatment-related adverse events	60 months
Primary	Change in enzyme expression profile	Serum level of AAV8-hCocH gene expression	Baseline, 24 months
Secondary	Maximum Observed Plasma Concentration (Cmax)	Cmax is measured as the peak concentration of AAV8 in the blood after intravenous infusion	24 months
Secondary	Time of peak concentration (tmax)	The time to maximum plasma concentration of AAV8 in the blood after intravenous infusion	24 months
Secondary	Half-Life (t1/2)	The time for plasma concentration of AAV8 in the blood to be reduced to exactly half of starting concentration	24 months
Secondary	Area under the Concentration-Time Curve (AUC)	AUC is a measure of the AAV8 serum concentration over time. Used to characterize drug absorption.	24 months